Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 5/20 | 0.55 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.55 |
| ▸ | ITGB7 | P26010 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ITGB3 | P05106 | 7/20 | 0.52 |
| ▸ | ITGAV | P06756 | 1/20 | 0.52 |
| ▸ | ITGA2B | P08514 | 6/20 | 0.50 |
| ▸ | MME | P08473 | 3/20 | 0.50 |
| ▸ | ACE | P12821 | 3/20 | 0.50 |
| ▸ | CPA1 | P15085 | 3/20 | 0.50 |
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.50 |
| ▸ | FPR2 | P25090 | 1/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | PPARA | Q07869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16124615 | 0.88 | MME (0.49) | ITGB1ITGA4ITGB3ITGAVMME | |
| SCHEMBL16124658 | 0.85 | MAPT (0.47) | — | |
| SCHEMBL5259390 | 0.84 | MME (0.56) | ITGB1ITGA4ITGB7ITGB3ITGA2B | |
| SCHEMBL1833280 | 0.84 | MME (0.56) | ITGB1ITGA4ITGB7ITGB3ITGA2B | |
| SCHEMBL16124678 | 0.84 | MAPT (0.65) | — | |
| SCHEMBL13416755 | 0.84 | ITGB1 (0.52) | ITGB1ITGA4ITGB7KMT2AITGB3 | |
| SCHEMBL13396591 | 0.82 | ITGB1 (0.50) | ITGB1ITGA4ITGB7KMT2AITGB3 | |
| SCHEMBL12150054 | 0.81 | FAAH (0.55) | ITGB1ITGA4ITGB7ACEACE2 | |
| SCHEMBL28965835 | 0.81 | PTPN1 (0.66) | KMT2AITGB3ITGA2BMMEACE | |
| SCHEMBL28965836 | 0.81 | PTPN1 (0.66) | KMT2AITGB3ITGA2BMMEACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024043313-A1 | REVERSIBLE THERMOCHROMIC COMPOSITION, MICROENCAPSULATED PIGMENT USING SAID REVERSIBLE THERMOCHROMIC COMPOSITION, WRITING TOOL, AND TOY | 三菱ケミカル株式会社 | 2024-02-29 | — | — | WO | disclosed |
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NICOX SA (FR) | 2014-09-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140288142-A1 | NITRIC OXIDE DONOR COMPOUNDS | NOS3, NOS2, NOS1 | ITGB1 203/4885ITGA4 773/4885ITGB7 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.